[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL NEWBORN SCREENING MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL NEWBORN SCREENING MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL NEWBORN SCREENING MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 INSTRUMENTCONSUMABLES

6 GLOBAL NEWBORN SCREENING MARKET, BY TEST TYPE
6.1 OVERVIEW
6.2 BLOOD TEST
6.3 HEARING SCREENING TEST
6.4 HEART SCREENING

7 GLOBAL NEWBORN SCREENING MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 TANDEM MASS SPECTROMETRY (TMS)
7.3 MOLECULAR ASSAYS
7.4 IMMUNOASSAYS AND ENZYMATIC ASSAYS
7.5 HEARING SCREEN TECHNOLOGY
7.6 PULSE OXIMETRY SCREENING TECHNOLOGY
7.7 OTHERS

8 GLOBAL NEWBORN SCREENING MARKET, BY END-USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 CLINICAL LABORATORIES 

9 GLOBAL NEWBORN SCREENING MARKET, BY GEOGRAPHY
9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO

9.3 EUROPE

9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3. 1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE

9.4 ASIA PACIFIC

9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC

9.5 MIDDLE EAST & AFRICA

9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA

9.6 SOUTH AMERICA

9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA

10 GLOBAL NEWBORN SCREENING MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES

11 COMPANY PROFILES

11.1 AB SCIEX LLC
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS

11.2 AGILENT TECHNOLOGIES INCORPORATED
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS

11.3 BIO-RAD LABORATORIES INCORPORATED
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS

11.4 COVIDIEN PLC
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS

11.5 GE HEALTHCARE
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS

11.6 PERKINELMER INCORPORATED
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS

11.7 MASIMO CORPORATION
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS

11.8. NATUS MEDICAL INCORPORATED
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS

11.9 TRIVITRON HEALTHCARE
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS

11.10 WATERS CORPORATION
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS